Efficacy of sofosbuvir plus ribavirin with peginterferon–alfa in patients with hepatitis C virus genotype 3 infection in Indian population.

Hilal Ahmed Tali; Rubiya Ryhan; Irshad Ahmad Tali; Falak Ara

Volume : VIII, Issue : IV, April - 2019

Efficacy of sofosbuvir plus ribavirin with peginterferon–alfa in patients with hepatitis C virus genotype 3 infection in Indian population.

Hilal Ahmed Tali, Rubiya Ryhan, Irshad Ahmad Tali, Falak Ara

Abstract :

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. Chronic hepatitis C and its complications impose a substantial burden on affected patients, healthcare systems and society. The introduction of direct acting antiviral agents, in particular sofosbuvir (SOF), has revolutionized the treatment for chronic hepatitis C virus. With SOF–based regimens, we have achieved high cure rates, decreased the duration of treatment and IFN–free treatment regimens have been made possible. AIMS AND OBJECTIVES To assess the treatment efficacy of sofosbuvir plus ribavarin with peginterferon–alfa in chronic hepatitis C infected patients of genotype 3. MATERIALS AND METHODS All the consecutive chronic hepatitis C, genotype 3 infected patients from outpatient and inpatient departments, fulfilling the inclusion and exclusion criteria were enrolled in the study. A total of 30 patients were included in study. Patients received 12 weeks treatment of Sofosbuvir plus Ribavirin plus peg interferon (SPR). Patients were monitored by clinical and standard laboratory tests on follow up visit to OPD.HCV RNA was measured at baseline, 4 week and at the end of treatment. After the completion of treatment protocol, these patients were followed for further 12 weeks and then quantitative HCV RNA level was done to check SVR12. Results:The overall sustained virological response at 12 weeks (SVR12) was achieved 90%.In cirrhotic patients SVR12 was achieved 70% patients while all non cirrhotic 100% patients have achieved SVR12. Conclusion: Triple drug regimen (Sofosbuvir, Pegylated Interferon and Ribavirin) had showed a better overall treatment response. The overall treatment response was relatively lower in cirrhotic patients. Triple drug therapy could be still alternative treatment regimen for hepatitis C with genotype 3 patients who are Interferon eligible .